Value proposition : Cost avoidance

Reduce attrition rate

Today, 75% of R&D spending produces failure. We propose technological partnering and services to better anticipate clinical tolerance of drug candidates at the pre-clinical stage using either the Mitosafe® or the Mitostream® technology. Our expertise will allow you to gain confidence in safety better and faster reducing the cost due to late attrition.

Post-marketing withdrawal or reduction of indications occurs in 20% of marketed drugs. Rare events are difficult to predict but can be flagged using the novel and pertinent system biology technology Mitostream® developed by ICDD.

We offer you to optimize your drug development process delivering confidence in care to the patient.

Increase success

Identifying responders and tolerant patients to your therapies warrant success in demonstrating their efficacy in this targeted population. ICDD develops proteomic programs to select the pertinent patient population to your treatment using its unique Promembrane® technology.